Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Rathbone, John ^b   Deeks, Jonathan J ^c   Soares Weiser, Karla ^a  

^a Enhance Reviews   (Israel)

^b INSTITUTE OF MENTAL HEALTH   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antipsychotic agents adverse effects ; Dyskinesia, drug induced *drug therapy; etiology ; GABA agonists *therapeutic use ; Humans; Randomized controlled trials as topic

Indexed keywords

4 AMINO 5 HEXYNOIC ACID; 4 AMINOBUTYRIC ACID; BACLOFEN; GABOXADOL; MUSCIMOL; PLACEBO; PROGABIDE; VALPROIC ACID; VIGABATRIN;

BIPOLAR DISORDER; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; HUMAN; MENTAL HEALTH; NEUROLEPTIC MALIGNANT SYNDROME; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77950146283     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000203.pub2     Document Type: Review

References (74)

1. Ananth 1987 {published data only} * Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C. Baclofen in the treatment of tardive dyskinesia. Current Therapeutic Research 1987;42(1):111-4.
2. Burner 1989 {published data only} * Burner M, Giroux C, L'Heritier C, Garreau M, Morselli PL. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunction 1989;2(6):289-96.
3. Fisk 1987 {published data only} Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia - revisited. British Journal of Psychiatry 1987;150:542-6.
4. Gerlach 1978 {published data only} Gerlach J. The relationship between parkisonism and tardive dyskinesia. American Journal of Psychiatry 1977;134(7):781-4.
5. * Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology Berlin 1978;56(2):145-51.
6. Linnoila 1976 {published data only} * Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry 1976;129:114-9.
7. UNair 1978 {published data only} * Nair NPV, Lal S, Schwartz G, Thavundayil JX. Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies. Advances in Biochemical Psychopharmacology 1980;24:437-41.
8. Nair NPV, Yassa R, Ruiz-Navarro J, Schwartz G. Baclofen in the treatment of tardive dyskinesia. American Journal of Psychiatry 1978;135:1562-3.
9. Stewart 1982 {published data only} Stewart RM, Rollins J, Beckam B, Roffman M. Baclofen for tardive dyskinesia: a double-blind placebo-controlled trial. Neurology 1982;32(4 II):A114.
10. * Stewart RM, Rollins J, Beckam B, Roffman M. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clinical Neuropharmacology 1982;5(4):365-73.
11. Thaker 1987 {published data only} * Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA. Brain gamma-aminobutyric-acid abnormality in tardive dyskinesia: reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Archives of General Psychiatry 1987;44(6):522-9.
12. Casey 1979 {published data only} * Casey DE, Hammerstad JP. Sodium valproate in tardive dyskinesia. Journal of Clinical Psychiatry 1979;40:483-5.
13. Casey 1980 {published data only} Casey DE, Gerlach J, Magelund G, Christensen TR. Gamma-acetylenic GABA in tardive dyskinesia. Advances in Biochemical Psychopharmacology 1980;24:577-80.
14. * Casey DE, Gerlach J, Magelund G, Christensen TR. Gamma-acetylenic GABA in tardive dyskinesia. Archives of General Psychiatry 1980;37(12):1376-9.
15. Cassady 1992 {published data only} * Cassady SL, Thaker GK, Moran M, Birt A, Tamminga CA. GABA agonist induced changes in motor, oculomotor and attention measures correlate in schizophrenics with tardive dyskinesia. Biological Psychiatry 1992;32:302-11.
16. Cassady 1993 {published data only} * Cassady SL, Thaker GK, Tamminga CA. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients. Psychopharmacology Bulletin 1993;29(2):236-40.
17. Chien 1978 {published data only} * Chien C, Jung K, Ross-Townsend A. Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacology Bulletin 1978;14(2):20-2. [MEDLINE: 1978179481]
18. Danion 1984 {published data only} * Danion JM, Singer L, Tell G, Schechter P. Gamma-vinyl-GABA et dyskinesies tardives: une etude en simple insu contre placebo. Annales Medico-Psychologiques Paris 1984;142(1):101-10.
19. Frangos 1980 {published data only} * Frangos E, Athanasenas E. Lioresal in the treatment of neuroleptic-induced tardive dyskinesia. Progress in Neuropsychopharmacology. Pergamon Press, 1980; Vol. 12th CINP Congress Supplement.
20. Friis 1983 {published data only} * Friis T, Rosted-Christensen T, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind crossover study with placebo. Acta Psychiatrica Scandinavica 1983;67(3):178-87. [MEDLINE: 1983227217]
21. Gibson 1978 {published data only} * Gibson AC. Sodium valproate and tardive dyskinesia. British Journal of Psychiatry 1978;133:82.
22. Glazer 1985 {published data only} * Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology 1985;87(4):480-3.
23. Gulmann 1976 {published data only} * Gulmann NC, Bahr B, Andersen B, Eliassen HM. A double-blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 1976;54(4):287-93. [MEDLINE: 77062570; : PMID 793304]
24. Korsgaard 1976 {published data only} * Korsgaard S. Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia. Acta Psychiatrica Scandinavica 1976;54 (1):17-24.
25. Korsgaard 1982 a {published data only} * Korsgaard S, Casey DE, Gerlach J, Hetmar O, Kaldan B, Mikkelsen LB. The effect of tetrahydroisooxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric-acid agonist. Archives of General Psychiatry 1982;39(9):1017-21.
26. Korsgaard 1983 {published data only} * Korsgaard S, Casey DE, Gerlach J. Effect of gamma-vinyl-GABA in tardive dyskinesia. Psychiatry Research 1983;8:261-9.
27. Lambert 1982 {published data only} * Lambert PA, Cantiniaux P, Chabannes JP, Tell GP, Schechter PJ, Koch-Weser J. Essai therapeutique du gamma-vinyl-GABA, un inhibiteur de la GABA-transaminase, dans les dyskinesies tardives induites par les neuroleptiques. L'Encephale 1982;8(3):371-6.
28. Monteleone 1988 {published data only} * Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L. Prolactin response to sodium valproate in shizophrenics with and without tardive dyskinesia. Psychopharmacology 1988;96:223-6.
29. Morselli 1985 {published data only} * Morselli PL, Fournier V, Bossi L, Musch B. Clinical activity of GABA agonists in neuroleptic and L-dopa-induced dyskinesia. Psychopharmacology 1985;2(Suppl): 128-36. [MEDLINE: 1985216407]
30. Nagao 1979 {published data only} Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biological Psychiatry 1979;14(3):509-23.
31. Nasrallah 1985 {published data only} * Nasrallah HA, Dunner FJ, McCalley-Whitters M. A placebo-controlled trial of valproate in tardive dyskinesia. Biological Psychiatry 1985;20(2):205-8.
32. Nasrallah 1986 {published data only} * Nasrallah HA, Dunner FJ, McCalley-Whitters M, Smith RE. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management. Journal of Clinical Psychiatry 1986;47(2):56-9.
33. Raptis 1990 {published data only} Raptis C, Garcia-Borreguero D, Webef MM, Sode M, Bremer D, Emrich HM. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. Acta Psychatrica Scandinavica 1990;81:162-7.
34. Rondot 1987 {published data only} Bathien N, Sevestre P, Rondot P, Morselli PL, van Landeghem V. The effect of progabide, a specific GABAergic agonist, on neuroleptic-induced tardive dyskinesia - a result of a pilot study. Abstracts of 13th Collegium Internationale Neuropsychopharmacologicum Congress. 1982.
35. * Rondot P, Bathien N. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study. Advances in Neurology 1987;45: 361-6.
36. Simpson 1978 {published data only} * Simpson GM, Lee JH, Shrivastava RK, Branchey MH. Baclofen in the treatment of tardive dyskinesia and schizophrenia. Psychopharmacology Bulletin 1978;14(2):16-8.
37. Stahl 1985 {published data only} * Stahl SM, Thornton JE, Simpson ML, Berger PA, Napoliello MJ. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biological Psychiatry 1985;20(8):888-93.
38. Tamminga 1978 {published data only} * Tamminga CA, Crayton JW, Chase TN. Muscimol: GABA agonist therapy in schizophrenia. American Journal of Psychiatry 1978;135:746-7. [MEDLINE: 78184769; : PMID 350058]
39. Tamminga 1979 {published data only} * Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Archives of General Psychiatry 1979;36:595-8.
40. Tamminga 1983 {published data only} Nguyen JA, Thaker GK, Tamminga CA. Gamma-aminobutyric-acid (GABA) pathways in tardive dyskinesia. Psychiatric Annals 1989;19(6):302-9.
41. * Tamminga CA, Thaker GK, Ferraro TN, Hare TA. GABA agonist treatment improves tardive dyskinesia. Lancet 1983;2:97-8.
42. Tamminga CA, Thaker GK, Goldberg ST. Tardive dyskinesia: GABA agonist treatment. In: Usdin E, Carlsson A, Dahlstrom A, Engel J editor(s). Catecholamines: neuropharmacology and central nervous system - therapeutic aspects. New York: Alan R Liss, 1994.
43. Thaker GK, Hare TA, Tamminga CA. GABA system: clinical research and treatment of tardive dyskinesia. Modern Problems in Pharmacopsychiatry 1983;21:155-67.
44. Tamminga 1984 {published data only} Tamminga CA, Thaker GK, Goldberg ST. Tardive dyskinesia: GABA agonist treatment. In: Usdin E, Carlsson A, Dahlstrom A, Engel J editor(s). Catecholamines: Neuropharmacology and central nervous system - therapeutic aspects. Alan R Liss, Inc, 1984:69-72. [MEDLINE: 78184769; : PMID 350058]
45. Tell 1981 {published data only} * Tell GP, Schechter PJ, Koch-Weser J, Cantiniaux P, Chabannes JP, Lambert PA. Effects of gamma-vinyl GABA. New England Journal of Medicine 1981;305(10): 581-2.
46. Korsgaard 1982 b {published data only} Korsgaard S, Casey D, Gerlach J. GABA agonist treatment of tardive dyskinesia. 13th Congress of Collegium Internationale Neuro-psychopharmacologicum; 1982 Jun 20-25; Jerusalem, Israel. 1982. [MEDLINE: 97353489; : PsycINFO 1997-06666-008; PMID 9209730]
47. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [: GABATD020600]
48. APA 1992 American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992.
49. Barnes 1983 Barnes TRE, Rossor M, Trauer T. A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals. Journal of Neurology, Neurosurgery and Psychiatry 1983;46:540-6.
50. Barnes 1988 Barnes TRE. Tardive dyskinesia: risk factors, pathophysiology and treatment. In: Granville-Grossman K editor(s). Recent Advances in Clinical Psychiatry. Vol. 6, London: Churchill Livingstone, 1988.
51. Barnes 1993 Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: Barnes TRE editor(s). Antipsychotic drugs and their side-effects. London: Academic Press, Harcourt Brace & Company, 1993.
52. Bergen 1984 Bergen JA, Griffiths DA, Rey JM, Beumont PJV. Tardive dyskinesia: fluctuating patient or fluctuating rater. British Journal of Psychiatry 1984;144:498-502. [MEDLINE: 1984232883]
53. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
54. Casey 1994 Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994.
55. Clarke 2003 Clarke M, Oxman, AD (Eds.). Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. The Cochrane Library. Oxford, England: Update Software, 2003, issue Issue 2.
56. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
57. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
58. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109): 629-34.
59. Gardos 1994 Gardos G, Cole JO. The treatment of tardive dyskinesia. In: Bloom FE, Kupfer DJ editor(s). Psychopharmacology. The Fourth Generation of Progress. Raven Press, 1994.
60. Gerlach 1976 Gerlach J, Thorsen K. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. International Pharmacopsychiatry 1976;11(1):1-7. [MEDLINE: 1976166955]
61. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. Journal of American Epidemiology 1999; 149:876-83.
62. Gunne 1984 Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347-9.
63. Guy 1976 Guy W. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health Publication No. 76-338. Washington, DC: US Government Printing Office, 1976.
64. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
65. Honigfeld 1966 Honigfeld G, Gillis RD, Klett CJ. NOSIE-30: A treatment-sensitive ward behavior scale. Psychological Reports 1966;19:180-2.
66. Jeste 1982 Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guilford Press, 1982.
67. Jeste 1988 Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology 1988;8(4 Suppl):38S-48S. [MEDLINE: 1989123931]
68. Krawiecka 1977 Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica 1977;55(4):299-308. [MEDLINE: 1977178605]
69. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
70. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
71. Schooler 1993 Schooler NR, Keith SJ. The clinical research base for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29(4):431-46. [MEDLINE: 1994367166]
72. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273: 408-12.
73. Simpson 1979 Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology (Berlin) 1979;64(2):171-9. [MEDLINE: 1979224334]
74. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]